JP2019509318A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509318A5
JP2019509318A5 JP2018549896A JP2018549896A JP2019509318A5 JP 2019509318 A5 JP2019509318 A5 JP 2019509318A5 JP 2018549896 A JP2018549896 A JP 2018549896A JP 2018549896 A JP2018549896 A JP 2018549896A JP 2019509318 A5 JP2019509318 A5 JP 2019509318A5
Authority
JP
Japan
Prior art keywords
composition
subject
clostridium difficile
difficile infection
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549896A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2017165729A5 (cg-RX-API-DMAC7.html
JP7458706B2 (ja
JP2019509318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/023958 external-priority patent/WO2017165729A1/en
Publication of JP2019509318A publication Critical patent/JP2019509318A/ja
Publication of JP2019509318A5 publication Critical patent/JP2019509318A5/ja
Priority to JP2022076605A priority Critical patent/JP2022115985A/ja
Priority to JP2023183167A priority patent/JP2024023187A/ja
Publication of JPWO2017165729A5 publication Critical patent/JPWO2017165729A5/ja
Application granted granted Critical
Publication of JP7458706B2 publication Critical patent/JP7458706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549896A 2016-03-24 2017-03-24 クロストリジウム・ディフィシル感染を処置及び予防するための方法 Active JP7458706B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022076605A JP2022115985A (ja) 2016-03-24 2022-05-06 クロストリジウム・ディフィシル感染を処置及び予防するための方法
JP2023183167A JP2024023187A (ja) 2016-03-24 2023-10-25 クロストリジウム・ディフィシル感染を処置及び予防するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US62/312,996 2016-03-24
US201662320053P 2016-04-08 2016-04-08
US62/320,053 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076605A Division JP2022115985A (ja) 2016-03-24 2022-05-06 クロストリジウム・ディフィシル感染を処置及び予防するための方法

Publications (4)

Publication Number Publication Date
JP2019509318A JP2019509318A (ja) 2019-04-04
JP2019509318A5 true JP2019509318A5 (cg-RX-API-DMAC7.html) 2020-04-30
JPWO2017165729A5 JPWO2017165729A5 (cg-RX-API-DMAC7.html) 2024-01-09
JP7458706B2 JP7458706B2 (ja) 2024-04-01

Family

ID=59900751

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018549896A Active JP7458706B2 (ja) 2016-03-24 2017-03-24 クロストリジウム・ディフィシル感染を処置及び予防するための方法
JP2022076605A Pending JP2022115985A (ja) 2016-03-24 2022-05-06 クロストリジウム・ディフィシル感染を処置及び予防するための方法
JP2023183167A Pending JP2024023187A (ja) 2016-03-24 2023-10-25 クロストリジウム・ディフィシル感染を処置及び予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022076605A Pending JP2022115985A (ja) 2016-03-24 2022-05-06 クロストリジウム・ディフィシル感染を処置及び予防するための方法
JP2023183167A Pending JP2024023187A (ja) 2016-03-24 2023-10-25 クロストリジウム・ディフィシル感染を処置及び予防するための方法

Country Status (13)

Country Link
US (3) US20170319603A1 (cg-RX-API-DMAC7.html)
EP (1) EP3432891A4 (cg-RX-API-DMAC7.html)
JP (3) JP7458706B2 (cg-RX-API-DMAC7.html)
CN (2) CN119454720A (cg-RX-API-DMAC7.html)
AU (3) AU2017238644B2 (cg-RX-API-DMAC7.html)
BR (2) BR122024000249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018872A1 (cg-RX-API-DMAC7.html)
MX (2) MX2018011413A (cg-RX-API-DMAC7.html)
MY (1) MY197627A (cg-RX-API-DMAC7.html)
PH (1) PH12018502020A1 (cg-RX-API-DMAC7.html)
RU (1) RU2751509C1 (cg-RX-API-DMAC7.html)
SG (2) SG11201808246SA (cg-RX-API-DMAC7.html)
WO (1) WO2017165729A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
MY200446A (en) * 2016-11-01 2023-12-26 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
CN113164456A (zh) * 2018-09-04 2021-07-23 帕拉特克药品公司 使用四环素化合物治疗分枝杆菌感染的方法
CA3113221A1 (en) * 2018-10-10 2020-04-16 Nutri Co., Ltd. Preventive and/or therapeutic agent for clostridium difficile infection
CA3179596A1 (en) * 2020-06-11 2021-12-16 Tadeusz Warchol Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509340A (ja) * 1991-07-24 1994-10-20 ザ、プロクター、エンド、ギャンブル、カンパニー 抗菌治療方法及び組成物
CN1690047B (zh) * 2000-07-07 2010-10-06 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332547A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
RU2008121238A (ru) * 2005-12-22 2010-01-27 Вайет (Us) Способы лечения инфекций желудочно-кишечного тракта с применением тайгециклина
AU2007208214B2 (en) * 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202436282A (zh) * 2008-05-19 2024-09-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
CA2752020A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
EP2956006A4 (en) * 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo

Similar Documents

Publication Publication Date Title
JP2019509318A5 (cg-RX-API-DMAC7.html)
Goderska et al. Helicobacter pylori treatment: antibiotics or probiotics
Livermore Introduction: the challenge of multiresistance
Meini et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature
Chou et al. Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chryseobacterium indologenes bacteremia in an intensive care unit
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
RU2018140463A (ru) 9-аминометилминоциклиновые соединения и способы их применения для лечения инфекций мочевых путей (имп)
Wang et al. Clinical characteristics of infections caused by Roseomonas species and antimicrobial susceptibilities of the isolates
Brook et al. Management of postirradiation infection: lessons learned from animal models
Malangoni Necrotizing soft tissue infections: are we making any progress?
Cunha et al. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection
Matsuda et al. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia
Huband et al. Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)
Argentino et al. Prevention of recurrence of enteric peritonitis in peritoneal dialysis with Escherichia coli Nissle 1917: a case-series study
Rahamat-Langendoen et al. Disseminated Rhodococcus equi infection in a kidney transplant patient without initial pulmonary involvement
Vandenhende et al. Successful daptomycin lock therapy for implantable intra-arterial catheter infection in a patient with liver metastases of colon cancer
Hiyama et al. Significance of anaerobic bacteria in postoperative infection after radical cystectomy and urinary diversion or reconstruction
Larnè et al. Bacteremic meningitis due to Pasteurella multocida resistant to first line antibiotic therapy
Khamdamov et al. Assessment of the effectiveness of diagnosis and therapy of patients with chronic bacterial prostatitis
Saha et al. Antimicrobials in growth and development
Savvidou et al. Primary pyomyositis and disseminated septic pulmonary emboli: a reactivated staphylococcal infection?
Badejo et al. Bacteriology and clinical course of camel-bite wound infections
RU2614730C1 (ru) Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
JP7654000B2 (ja) テモシリンでの微生物腸内毒素症の管理
Konar et al. Nitrofurantoin in urinary tract infection: old is gold